Key Highlights
- BMY shares traded up 4.66% to $61.57, versus a prior close of $58.83.
- Recent Phase 3 data covered RYZ101, iberdomide and a lower dose of admilparant.
- Goldman Sachs upgraded the stock and HSBC issued a buy call.
- The dividend yield is about 4.10%, with a forward price-to-earnings ratio of 9.57.
- Q3 earnings are due Oct. 29.
Pharma Rotation and Upgrades Drive a 4.7% Gain
Bristol Myers Squibb (NYSE:BMY) shares traded up 4.66% to $61.57 as a healthcare rotation lifted pharma stocks to record sector highs. Investors favored defensives amid volatility in artificial intelligence stocks and oil-driven macro jitters.
The gain follows a 1.5% decline on Monday. Volume is running below average, a sign the move is not yet backed by heavy trading.
Phase 3 Results and Analyst Support Back the Move
Company-specific support includes recent positive Phase 3 data for RYZ101, iberdomide and a lower dose of admilparant. Goldman Sachs upgraded the stock, HSBC issued a buy call and RBC expects a Q3 revenue beat.
Consensus price target is about $64.88. Shares trade against a 52-week range of $42.52 to $68.64.
Low Valuation and a High Yield Meet Debt and Patent Risk
Bristol trades near 9.6 times forward earnings with a dividend yield of about 4.10%, and its market capitalization is about $125.77 billion. Those figures sit against roughly $43 billion in debt and the loss of exclusivity facing legacy blockbusters, the key debates for the stock.
The company is pursuing a portfolio transition toward newer growth products such as Breyanzi, Camzyos, Sotyktu and Cobenfy.
ESMO Presentations and Q3 Earnings Come Next
Investors will watch ESMO oncology presentations from Oct. 23 to 27, followed by Q3 earnings on Oct. 29. New growth product sales and any update on the patent transition are the main items to monitor.






Please wait processing your request...